Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.
AI Chatbot Deployed To Target Drug Resistance
Scientists have developed an AI chatbot similar to ChatGPT to help governments devise effective policies for battling drug resistance.